Monogenic/Single Gene Disorders (PGT-M) &
Chromosomal Structural Rearrangements (PGT-SR)
Previda®-DX is a personalized test tailored to patients’ specific genetic background. Patients interested in Previda®-DX are required to provide a report of their genetic records to assess if the test can be performed. After reviewing the patient’s gene report, scientists at Progenesis design a test to detect the mutation or rearrangement. Our team of laboratory technicians will optimize the test by using parental DNA to confirm the abnormality. The final test is performed on a biopsy from the embryo and includes testing for the specific mutation and/or chromosomal rearrangement in the embryo (PGT-M and PGT-SR) as well as 24-chromosome screening for aneuploidies (PGT-A).
Progenesis is the first company in the U.S. to use next generation sequencing (NGS) technology for preimplantation genetic diagnosis (PGT-M and PGT-SR). NGS is far superior to the current industry standard (real-time PCR).
NGS combines the power of single mutation detection and complete 24-chromosome screening. In addition, NGS offers the most accurate and sensitive technology to screen for unbalanced translocation events which are difficult to detect using traditional PCR and fluorescent in-situ hybridization based techniques.
Progenesis is a San Diego based company that develops and offers genetic testing services for patients throughout their family planning journey. Progenesis was the first company in the U.S. to offer Next Generation Sequencing (NGS) for preimplantation genetic testing. Through optimization of the NGS platform, Progenesis confidently maintains the most accurate testing in the IVF field with the lowest rate of mosaicism.